Two inactivated COVID-19 vaccines for the Omicron variant developed by China National Pharmaceutical Group Co., Ltd. (Sinopharm) have been approved to start clinical trials in Hong Kong.
Sinopharm had immediately established a task force to carry out research into and development of an Omicron vaccine after the outbreak of the COVID-19 Omicron variant.
It also worked together with the University of Hong Kong and applied for clinical trials as soon as the vaccines were developed.
Two inactivated COVID-19 vaccines for the Omicron variant have been developed by China National Pharmaceutical Group Co., Ltd. and have obtained approval for clinical trials in Hong Kong. [Photo/sasac.gov.cn]
Next, Sinopharm will carry out clinical trials of the vaccines on people of 18 years of age and above to evaluate their safety and immunogenicity.
(Executive editor: Niu Yilin)
